HRP20000162B1 - Amorphous torasemide modification - Google Patents

Amorphous torasemide modification

Info

Publication number
HRP20000162B1
HRP20000162B1 HR20000162A HRP20000162A HRP20000162B1 HR P20000162 B1 HRP20000162 B1 HR P20000162B1 HR 20000162 A HR20000162 A HR 20000162A HR P20000162 A HRP20000162 A HR P20000162A HR P20000162 B1 HRP20000162 B1 HR P20000162B1
Authority
HR
Croatia
Prior art keywords
torasemide modification
amorphous torasemide
amorphous
modification
torasemide
Prior art date
Application number
HR20000162A
Other languages
English (en)
Inventor
Filic Darko
Dumic Miljenko
Klepic Božena
Danilovski Aleksandar
Tu­A Marijan
Original Assignee
Pliva D D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva D D filed Critical Pliva D D
Priority to HR20000162A priority Critical patent/HRP20000162B1/xx
Priority to ARP000102019A priority patent/AR023788A1/es
Priority to ES00920938T priority patent/ES2213006T3/es
Priority to BR0017175-1A priority patent/BR0017175A/pt
Priority to CZ20023436A priority patent/CZ20023436A3/cs
Priority to PT00920938T priority patent/PT1272470E/pt
Priority to PL00357154A priority patent/PL357154A1/xx
Priority to EEP200200534A priority patent/EE200200534A/xx
Priority to DE60007360T priority patent/DE60007360T2/de
Priority to HU0300596A priority patent/HUP0300596A3/hu
Priority to SK1509-2002A priority patent/SK15092002A3/sk
Priority to EA200201003A priority patent/EA004950B1/ru
Priority to AU2000241348A priority patent/AU2000241348A1/en
Priority to EP00920938A priority patent/EP1272470B1/en
Priority to GE4937A priority patent/GEP20043300B/en
Priority to KR1020027012411A priority patent/KR20020093847A/ko
Priority to US10/239,024 priority patent/US6767917B1/en
Priority to PCT/HR2000/000011 priority patent/WO2001070694A1/en
Priority to IL15180100A priority patent/IL151801A0/xx
Priority to JP2001568906A priority patent/JP2003528083A/ja
Priority to MXPA02009210A priority patent/MXPA02009210A/es
Priority to CA002401908A priority patent/CA2401908A1/en
Priority to YU70502A priority patent/YU70502A/sh
Priority to CNB008194319A priority patent/CN1211368C/zh
Priority to AT00920938T priority patent/ATE256662T1/de
Priority to SI200030301T priority patent/SI1272470T1/xx
Publication of HRP20000162A2 publication Critical patent/HRP20000162A2/hr
Priority to IS6551A priority patent/IS6551A/is
Priority to NO20024464A priority patent/NO20024464L/no
Priority to ZA200208309A priority patent/ZA200208309B/en
Priority to BG107208A priority patent/BG107208A/xx
Publication of HRP20000162B1 publication Critical patent/HRP20000162B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
HR20000162A 2000-03-20 2000-03-20 Amorphous torasemide modification HRP20000162B1 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
HR20000162A HRP20000162B1 (en) 2000-03-20 2000-03-20 Amorphous torasemide modification
ARP000102019A AR023788A1 (es) 2000-03-20 2000-04-28 Modificacion amorfa de torasemida
KR1020027012411A KR20020093847A (ko) 2000-03-20 2000-05-02 무정형 토라세미드 변형물
PCT/HR2000/000011 WO2001070694A1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification
BR0017175-1A BR0017175A (pt) 2000-03-20 2000-05-02 Modificação da torasemida amorfa
PT00920938T PT1272470E (pt) 2000-03-20 2000-05-02 Forma modificada da torasemida amorfa
PL00357154A PL357154A1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification
EEP200200534A EE200200534A (et) 2000-03-20 2000-05-02 Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaat
DE60007360T DE60007360T2 (de) 2000-03-20 2000-05-02 Amorphe modifikation von torasemid
HU0300596A HUP0300596A3 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification, process for its preparation its use and pharmaceutical compositions containing it
SK1509-2002A SK15092002A3 (sk) 2000-03-20 2000-05-02 Amorfná modifikácia torasemidu, spôsob jej prípravy a farmaceutický prostriedok obsahujúci túto modifikáciu
EA200201003A EA004950B1 (ru) 2000-03-20 2000-05-02 Аморфная модификация торасемида
AU2000241348A AU2000241348A1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification
EP00920938A EP1272470B1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification
GE4937A GEP20043300B (en) 2000-03-20 2000-05-02 Amorphous Torasemide Modification
ES00920938T ES2213006T3 (es) 2000-03-20 2000-05-02 Forma modificada de torasemida amorfa.
US10/239,024 US6767917B1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification
CZ20023436A CZ20023436A3 (cs) 2000-03-20 2000-05-02 Amorfní modifikace torasemidu, způsob její přípravy a přípravy farmaceutického prostředku obsahujícího tuto modifikaci
IL15180100A IL151801A0 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification
JP2001568906A JP2003528083A (ja) 2000-03-20 2000-05-02 非晶質トラセミド変態
MXPA02009210A MXPA02009210A (es) 2000-03-20 2000-05-02 Modificacion amorfa de torasemida.
CA002401908A CA2401908A1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification
YU70502A YU70502A (sh) 2000-03-20 2000-05-02 Amorfna modifikacija torasemida
CNB008194319A CN1211368C (zh) 2000-03-20 2000-05-02 无定形的托拉塞米变体
AT00920938T ATE256662T1 (de) 2000-03-20 2000-05-02 Amorphe modifikation von torasemid
SI200030301T SI1272470T1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification
IS6551A IS6551A (is) 2000-03-20 2002-09-17 Formlaus torasemíð umbreyting
NO20024464A NO20024464L (no) 2000-03-20 2002-09-18 Amorf Torasemide-modifikasjon
ZA200208309A ZA200208309B (en) 2000-03-20 2002-10-15 Amorphous torasemide modification.
BG107208A BG107208A (en) 2000-03-20 2002-10-21 Amorphous torasemide modification

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20000162A HRP20000162B1 (en) 2000-03-20 2000-03-20 Amorphous torasemide modification

Publications (2)

Publication Number Publication Date
HRP20000162A2 HRP20000162A2 (en) 2001-12-31
HRP20000162B1 true HRP20000162B1 (en) 2004-06-30

Family

ID=10947070

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000162A HRP20000162B1 (en) 2000-03-20 2000-03-20 Amorphous torasemide modification

Country Status (29)

Country Link
US (1) US6767917B1 (xx)
EP (1) EP1272470B1 (xx)
JP (1) JP2003528083A (xx)
KR (1) KR20020093847A (xx)
CN (1) CN1211368C (xx)
AR (1) AR023788A1 (xx)
AT (1) ATE256662T1 (xx)
AU (1) AU2000241348A1 (xx)
BG (1) BG107208A (xx)
BR (1) BR0017175A (xx)
CA (1) CA2401908A1 (xx)
CZ (1) CZ20023436A3 (xx)
DE (1) DE60007360T2 (xx)
EA (1) EA004950B1 (xx)
EE (1) EE200200534A (xx)
ES (1) ES2213006T3 (xx)
GE (1) GEP20043300B (xx)
HR (1) HRP20000162B1 (xx)
HU (1) HUP0300596A3 (xx)
IL (1) IL151801A0 (xx)
IS (1) IS6551A (xx)
MX (1) MXPA02009210A (xx)
NO (1) NO20024464L (xx)
PL (1) PL357154A1 (xx)
PT (1) PT1272470E (xx)
SK (1) SK15092002A3 (xx)
WO (1) WO2001070694A1 (xx)
YU (1) YU70502A (xx)
ZA (1) ZA200208309B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465496B1 (en) * 1999-08-11 2002-10-15 Teva Pharmaceutical Industries, Ltd. Torsemide polymorphs
IN192178B (xx) 2001-08-03 2004-03-06 Ranbaxy Lab
CA2536967A1 (en) 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
JP2008531579A (ja) 2005-02-24 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強利尿化合物、組成物および使用方法
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
US6096779A (en) * 1995-02-22 2000-08-01 Hoechst Pharmaceuticals & Chemicals K.K. Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
IN182496B (xx) 1996-02-20 1999-04-17 Reddy Research Foundation
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6465496B1 (en) 1999-08-11 2002-10-15 Teva Pharmaceutical Industries, Ltd. Torsemide polymorphs

Also Published As

Publication number Publication date
DE60007360D1 (de) 2004-01-29
KR20020093847A (ko) 2002-12-16
IL151801A0 (en) 2003-04-10
PL357154A1 (en) 2004-07-12
EE200200534A (et) 2004-04-15
IS6551A (is) 2002-09-17
CN1452613A (zh) 2003-10-29
US6767917B1 (en) 2004-07-27
EA004950B1 (ru) 2004-10-28
JP2003528083A (ja) 2003-09-24
EP1272470B1 (en) 2003-12-17
PT1272470E (pt) 2004-05-31
CA2401908A1 (en) 2001-09-27
HUP0300596A2 (hu) 2003-07-28
WO2001070694A1 (en) 2001-09-27
ES2213006T3 (es) 2004-08-16
YU70502A (sh) 2006-01-16
EA200201003A1 (ru) 2003-02-27
ZA200208309B (en) 2003-10-15
GEP20043300B (en) 2004-02-10
ATE256662T1 (de) 2004-01-15
AR023788A1 (es) 2002-09-04
HRP20000162A2 (en) 2001-12-31
MXPA02009210A (es) 2004-09-06
WO2001070694A8 (en) 2002-03-21
EP1272470A1 (en) 2003-01-08
CZ20023436A3 (cs) 2003-03-12
SK15092002A3 (sk) 2003-05-02
AU2000241348A1 (en) 2001-10-03
DE60007360T2 (de) 2004-10-07
BR0017175A (pt) 2002-12-10
NO20024464L (no) 2002-09-20
BG107208A (en) 2003-07-31
CN1211368C (zh) 2005-07-20
HUP0300596A3 (en) 2005-08-29
NO20024464D0 (no) 2002-09-18

Similar Documents

Publication Publication Date Title
GB0011749D0 (en) Light-eminating devices
GB0015716D0 (en) Devices
AU3391801A (en) Pyridinylimidazoles
IL151020A0 (en) Substituted arylpyrazines
AU8274301A (en) Electro-powder
AU6227101A (en) Substituted iminoazines
AU6803901A (en) Bis-arylsulfones
AU5825501A (en) Substituted benzoylcyclohexenones
PL358119A1 (en) Substituted phenyluracils
AU6619001A (en) Liquid-pourers
IL151801A0 (en) Amorphous torasemide modification
AU9187601A (en) Triazolo-epothilones
AU4686401A (en) Hypotensors
AU3521202A (en) Application devices
AU4831301A (en) Gm-negative ehv-mutants
AU8756801A (en) Thienopyrrolidinones
AU2360402A (en) Substituted phenyluracils
SI1272470T1 (en) Amorphous torasemide modification
IL154457A0 (en) Mircronized torsemide
GB0028423D0 (en) Eductional aid
GB0028494D0 (en) Tassel-making aid
AU1702P (en) Trailblazer Xanthostemon chrysanthus
AU1852P (en) Tickit xTriticosecale
AU2117P (en) Gauka Gaura lindheimeri
TW452154U (en) Improved magnetic-sensing device

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090219

Year of fee payment: 10

PBON Lapse due to non-payment of renewal fee

Effective date: 20100321